IRulya Therapeutics Inc.

Report Phase 2 data for LAM-001 in bronchiolitis obliterans syndrome (BOS)

Deadline not yet reached (155 days left)

Announced: 9 Oct 2026
Due: 31 Mar 2027

Deadline
Met
Late
Not met
Today

What the company said

“LAM-001 is currently being evaluated in an ongoing Phase 2 trial in BOS, with data anticipated in the first quarter of 2027.”

SourceQuince Therapeutics, Inc. Form 8-K press release, 2026-10-09
FilingSEC filing index
Deadline as statedin the first quarter of 2027
Deadline used31 Mar 2027, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-QNCX-005923
Cite as https://keptindex.org/c/KI-C-2026-QNCX-005923/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Mar 2027.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: Phase 2 trial data for LAM-001 in BOS
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Quince Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-QNCX-005923 · Corrections policy